Hanff Erik, Lützow Moritz, Kayacelebi Arslan Arinc, Finkel Armin, Maassen Mirja, Yanchev Georgi Radoslavov, Haghikia Arash, Bavendiek Udo, Buck Anna, Lücke Thomas, Maassen Norbert, Tsikas Dimitrios
Centre of Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany.
Institute of Sport Medicine, Hannover Medical School, Hannover, Germany.
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 15;1047:207-214. doi: 10.1016/j.jchromb.2016.03.034. Epub 2016 Mar 24.
Creatinine in urine is a useful biochemical parameter to correct the urinary excretion rate of endogenous and exogenous substances. Nitrite (ONO) and nitrate (ONO) are metabolites of nitric oxide (NO), a signalling molecule with multiple biological functions. Under certain and standardized conditions, the concentration of nitrate in the urine is a suitable measure of whole body NO synthesis. The urinary nitrate-to-nitrite molar ratio (UR) may indicate nitrite-dependent renal carbonic anhydrase (CA) activity. In clinical studies, urine is commonly collected by spontaneous micturition. In those cases the nitrate and nitrite excretion must be corrected for creatinine excretion. Pentafluorobenzyl (PFB) bromide (PFB-Br) is a useful derivatization reagent of numerous inorganic and organic compounds, including urinary nitrite, nitrate and creatinine, for highly sensitive and specific quantitation by GC-MS. Here, we report on the simultaneous PFB-Br derivatization (60min, 50°C) of ONO, ONO, ONO, ONO, creatinine (d-Crea) and [methylo-H]creatinine (d-Crea) in acetonic dilutions of native human urine and plasma samples (4:1, v/v) and their simultaneous quantification by GC-MS as PFBNO, PFBNO, PFBONO, PFBONO, d-Crea-PFB and d-Crea-PFB, respectively. Electron capture negative-ion chemical ionization (ECNICI) of these derivatives generates anions due to [M-PFB], i.e., the starting analytes. Quantification is performed by selected-ion monitoring (SIM) of m/z 46 (ONO), m/z 47 (ONO), m/z 62 (ONO), m/z 63 (ONO), m/z 112 (d-Crea), and m/z 115 (d-Crea). Retention times were 2.97min for PFB-ONO/PFB-ONO, 3.1min for PFB-NO/PFB-NO, and 6.7min for d-Crea-PFB/d-Crea-PFB. We used this method to investigate the effects of long-term oral NaNO or NaCl (serving as placebo) supplementation (each 0.1mmol/kg body weight per day for 3 weeks) on creatinine excretion and UR in 17 healthy young men. Compared to NaCl (n=8), NaNO (n=9) supplementation increased UR (1709±355 vs. 369±77, P<0.05). Creatinine excretion did not differ between the groups (6.67±1.34mM vs. 5.72±1.27mM, P=0.57). The method is also applicable to human plasma. In 78 adults patients newly diagnosed for cerebrovascular disease (CVD), there was a close correlation (r=0.9833) between the creatinine concentrations measured in plasma by GC-ECNICI-MS and those measured in serum by an enzymatic assay. Creatinine-corrected plasma nitrate and nitrite concentrations (P=0.035 and P=0.004, respectively) but not their concentrations (P=0.68 and P=0.40, respectively) differ between male (n=54) and female (n=24) CVD patients. No such differences were found between preterm newborn boys (n=25) and girls (n=22). Like in urine, circulating creatinine may be useful to correct for gender-specific differences in plasma nitrite and nitrate in adults. Chronic NaNO supplementation to healthy young men does not affect renal CA-dependent nitrite excretion or creatinine synthesis and excretion.
尿肌酐是校正内源性和外源性物质尿排泄率的有用生化参数。亚硝酸盐(ONO)和硝酸盐(ONO)是一氧化氮(NO)的代谢产物,NO是一种具有多种生物学功能的信号分子。在特定的标准化条件下,尿中硝酸盐浓度是全身NO合成的合适指标。尿硝酸盐与亚硝酸盐的摩尔比(UR)可能指示依赖亚硝酸盐的肾碳酸酐酶(CA)活性。在临床研究中,尿液通常通过自然排尿收集。在这些情况下,硝酸盐和亚硝酸盐排泄必须根据肌酐排泄进行校正。五氟苄基(PFB)溴化物(PFB-Br)是许多无机和有机化合物(包括尿亚硝酸盐、硝酸盐和肌酐)的有用衍生化试剂,可通过气相色谱-质谱联用(GC-MS)进行高灵敏度和特异性定量。在此,我们报告了在天然人尿液和血浆样品(4:1,v/v)的丙酮稀释液中,ONO、ONO、ONO、ONO、肌酐(d-Crea)和[甲基-H]肌酐(d-Crea)同时进行PFB-Br衍生化(60分钟,50°C),并通过GC-MS分别作为PFBNO、PFBNO、PFBONO、PFBONO、d-Crea-PFB和d-Crea-PFB进行同时定量。这些衍生物的电子捕获负离子化学电离(ECNICI)由于[M-PFB]产生阴离子,即起始分析物。通过对m/z 46(ONO)、m/z 47(ONO)、m/z 62(ONO)、m/z 63(ONO)、m/z 112(d-Crea)和m/z 115(d-Crea)的选择离子监测(SIM)进行定量。PFB-ONO/PFB-ONO的保留时间为2.97分钟,PFB-NO/PFB-NO为3.1分钟,d-Crea-PFB/d-Crea-PFB为6.7分钟。我们使用该方法研究了长期口服NaNO或NaCl(作为安慰剂)补充剂(每天每千克体重各0.1mmol,共3周)对17名健康年轻男性肌酐排泄和UR的影响。与NaCl组(n = 8)相比,NaNO组(n = 9)补充剂使UR增加(1709±355对369±77,P<0.05)。两组之间的肌酐排泄没有差异(6.67±1.34mM对5.72±1.27mM,P = 0.57)。该方法也适用于人体血浆。在78名新诊断为脑血管疾病(CVD)的成年患者中,通过GC-ECNICI-MS测定的血浆肌酐浓度与通过酶法测定的血清肌酐浓度之间存在密切相关性(r = 0.9833)。男性(n = 54)和女性(n = 24)CVD患者之间,经肌酐校正的血浆硝酸盐和亚硝酸盐浓度(分别为P = 0.035和P = 0.004)存在差异,但未校正的浓度(分别为P = 0.68和P = 0.40)无差异。早产男婴(n = 25)和女婴(n = 22)之间未发现此类差异。与尿液一样,循环肌酐可能有助于校正成年人血浆中亚硝酸盐和硝酸盐的性别特异性差异。对健康年轻男性长期补充NaNO不会影响肾CA依赖性亚硝酸盐排泄或肌酐合成与排泄。